Follow
Philip Lowe
Philip Lowe
It's all in the dose Ltd
Verified email at itsallinthedose.com
Title
Cited by
Cited by
Year
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
HJ Lachmann, P Lowe, SD Felix, C Rordorf, K Leslie, S Madhoo, ...
Journal of Experimental Medicine 206 (5), 1029-1036, 2009
3532009
Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats
PJ LOWE, CS TEMPLE
Journal of pharmacy and pharmacology 46 (7), 547-552, 1994
2231994
Omalizumab in asthma: an update on recent developments
M Humbert, W Busse, NA Hanania, PJ Lowe, J Canvin, VJ Erpenbeck, ...
The Journal of Allergy and Clinical Immunology: In Practice 2 (5), 525-536. e1, 2014
2182014
Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects
JP Arm, I Bottoli, A Skerjanec, D Floch, A Groenewegen, S Maahs, ...
Clinical & Experimental Allergy 44 (11), 1371-1385, 2014
2132014
A mechanism‐based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab
N Hayashi, Y Tsukamoto, WM Sallas, PJ Lowe
British journal of clinical pharmacology 63 (5), 548-561, 2007
1862007
Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1 Monoclonal Antibody
A Chakraborty, S Tannenbaum, C Rordorf, PJ Lowe, D Floch, H Gram, ...
Clinical Pharmacokinetics 51 (6), e1-e18, 2012
1702012
Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE‐mediated) asthma
PJ Lowe, S Tannenbaum, A Gautier, P Jimenez
British journal of clinical pharmacology 68 (1), 61-76, 2009
1612009
Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations
RG Slavin, C Ferioli, SJ Tannenbaum, C Martin, M Blogg, PJ Lowe
Journal of Allergy and Clinical Immunology 123 (1), 107-113. e3, 2009
1582009
Omalizumab decreases IgE production in patients with allergic (IgE‐mediated) asthma; PKPD analysis of a biomarker, total IgE
PJ Lowe, D Renard
British journal of clinical pharmacology 72 (2), 306-320, 2011
1462011
Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2 [2-(-4-octylphenyl) ethyl] propane-1, 3-diol hydrochloride) in rats after oral and intravenous doses
GML Meno-Tetang, H Li, S Mis, N Pyszczynski, P Heining, P Lowe, ...
Drug metabolism and disposition 34 (9), 1480-1487, 2006
1402006
Hormonal regulation of hepatocyte tight junctional permeability
PJ Lowe, K Miyai, JH Steinbach, WGM Hardison
Am J Physiol 255 (4 Pt 1), G454-G461, 1988
1311988
Membrane lipid composition and susceptibility to bile salt damage
R Coleman, PJ Lowe, D Billington
Biochimica et Biophysica Acta (BBA)-Biomembranes 599 (1), 294-300, 1980
1281980
Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses
GM Gauvreau, JP Arm, LP Boulet, R Leigh, DW Cockcroft, BE Davis, ...
Journal of Allergy and Clinical Immunology 138 (4), 1051-1059, 2016
1222016
The effects of colchicine on secretion into bile of bile salts, phospholipids, cholesterol and plasma membrane enzymes: bile salts are secreted unaccompanied by phospholipids …
SG Barnwell, PJ Lowe, R Coleman
Biochemical Journal 220 (3), 723-731, 1984
1201984
On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach
GML Meno‐Tetang, PJ Lowe
Basic & clinical pharmacology & toxicology 96 (3), 182-192, 2005
1092005
Transcytosis and paracellular movements of horseradish peroxidase across liver parenchymal tissue from blood to bile. Effects of alpha-naphthylisothiocyanate and colchicine
PJ Lowe, KS Kan, SG Barnwell, RK Sharma, R Coleman
Biochemical Journal 229 (2), 529-537, 1985
1021985
Rapid kinetic analysis of the bile-salt-dependent secretion of phospholipid, cholesterol and a plasma-membrane enzyme into bile
PJ Lowe, SG Barnwell, R Coleman
Biochemical Journal 222 (3), 631-637, 1984
831984
On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development
PJ Lowe, Y Hijazi, O Luttringer, H Yin, R Sarangapani, D Howard
Xenobiotica 37 (10-11), 1331-1354, 2007
792007
Effect of taurochenodeoxycholate or tauroursodeoxycholate upon biliary output of phospholipids and plasma-membrane enzymes, and the extent of cell damage, in isolated perfused …
SG Barnwell, PJ Lowe, R Coleman
Biochemical Journal 216 (1), 107-111, 1983
781983
Membrane fluidity and bile salt damage
PJ Lowe, R Coleman
Biochimica et Biophysica Acta (BBA)-Biomembranes 640 (1), 55-65, 1981
781981
The system can't perform the operation now. Try again later.
Articles 1–20